An enzyme that drives the growth of an often-lethal childhood brain cancer may hold the key to a future treatment, says a McMaster University-led study.
With the support of adMare's industrial scientific expertise, research infrastructure and critical funding, Sheila Singh and Jakob Magolan will work on preventing the formation of metastases in brain cancer patients.
The post-treatment minimal residual disease (MRD) profiles of glioblastoma patients were mapped using single cell sequencing to find a genetic signature that predicted how the cancer would recur in each individual.
McMaster logo
McMaster logo
